Navigation Links
Nile Therapeutics to Transition to OTCQB Marketplace
Date:5/11/2011

and reporting with the Securities and Exchange Commission. The Company expects its common stock will continue to trade under the "NLTX" symbol on the computerized OTCQB system. Investors will be able to view Level II Real Time stock quotes for Nile at http://www.otcmarkets.com.

About Nile Therapeutics

Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's transition from The Nasdaq Capital Market to the OTCQB Marketplace, including the timing of trading of and the prospects for a market developing for Nile's securities on the OTCQB, are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's need to raise additional capital to fund its product development program
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
2. InVivo Therapeutics and The Miami Project to Cure Paralysis Form Strategic Research Collaboration to Develop Novel Treatments for Spinal Cord Injuries
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Cell Therapeutics Retires 7.5% Convertible Senior Notes
6. Talecris Biotherapeutics Announces First Quarter 2011 Results
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics
9. Proteon Therapeutics Initiates Patient Enrollment in Phase 2 Clinical Study of PRT-201 in Hemodialysis Patients
10. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
11. Precision Therapeutics ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Aug. 26, 2014 Trovagene, Inc. (NASDAQ: ... Dx Summit; Moving Assays to the Clinic ... Monitoring of Cell Free Tumor DNA in Urine." ... of its Precision Cancer Monitoring (PCM) platform and ... for the detection of tumor DNA mutations from ...
(Date:8/26/2014)... Aug. 26, 2014  That,s Nice LLC, a research-focused ... announced the formation of a new dedicated team that ... expanded team will combine current and new staff in ... Nice. Guy Tiene has ... the team. Tiene was previously Director of Marketing for ...
(Date:8/26/2014)... Boston, MA (PRWEB) August 26, 2014 ... to manage core research facilities , the ... of Kansas Cancer Center have chosen iLab Solutions' ... and effectively increase productivity. , "We are ... Center and KU Cancer Center signed on with ...
(Date:8/26/2014)... , Aug. 26, 2014 /PRNewswire-iReach/ -- The crowdfunding ... is in full effect on the popular crowdfunding platform ... their support for the biofeedback belt. The $75,000 funding ... mass-produce and distribute the product. Photo - ... small device worn on the lower back that silently ...
Breaking Biology Technology:Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4That's Nice Announces Expanded Offering For Strategic Content And Public Relations 2That's Nice Announces Expanded Offering For Strategic Content And Public Relations 3The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 3PosturePulse, A Biofeedback Posture-Improving Belt, Improves Posture While Sitting or Standing 2
... DIEGO -- In the Sept 9, 2010 issue of ... of concept studies that show its proprietary compound, NGP ... Alzheimer,s disease (AD) in a transgenic mouse model. ... the gamma secretase modulator (GSM) compound from NGP, the ...
... GAITHERSBURG, Md. Using a one-of-a-kind instrument designed and ... (NIST), an international team of researchers have "unveiled" a ... in graphene can split up into an unexpected and ... low temperatures and extremely high magnetic fields. Published in ...
... THE WOODLANDS, Texas, Sept. 9 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... president and chief executive officer, will present at the ... 16, 2010 at 9:10 a.m. Eastern Time. ...
Cached Biology Technology:Neurogenetic studies show proprietary compound reduces brain plaques linked to Alzheimer's 2NIST researchers hear puzzling new physics from graphene quartet's quantum harmonies 2NIST researchers hear puzzling new physics from graphene quartet's quantum harmonies 3Lexicon to Present at Stifel Nicolaus Healthcare Conference 2
(Date:8/26/2014)... colony of harmful bacteria, biofilms make the treatment ... a biofilm pose a significant health risk due ... and biofilm-protected bacteria account for some 80 percent ... 50 to 1,000 times more resistant to antibiotics ... may have stumbled onto a magic bullet," said ...
(Date:8/26/2014)... Ill. University of Illinois engineers are bringing ... The researchers developed a new continuous glucose monitoring ... and the wavelength shift is so precise that ... it for automatic insulin dosing - something ... strips. , "There are significant limitations to current ...
(Date:8/26/2014)... at the University of Illinois at Urbana-Champaign have ... paving the way for power-on-a-chip applications. , ... scale that amplify light and produce ultra-narrowband spectral ... electrical and computer engineering (ECE) at Illinois. "These ... power on a chip containing both electronic and ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3A glucose meter of a different color provides continuous monitoring 2A glucose meter of a different color provides continuous monitoring 3Symphony of nanoplasmonic and optical resonators produces laser-like light emission 2
... The efficacy of preimplantation genetic screening (PGS) has been ... over the past few years. None of the trials,carried ... or not. Now the European Society of Human,Reproduction and ... try to find out if a novel,method of doing ...
... what their football heroes can do with a football, the ... in excellent physical condition undoubtedly helps, few people actually believe ... into a Ronaldo. Now, scientists from the University of Queensland ... Dr. Robbie Wilson will talk about the details of this ...
... that the anti-malarial drug quinine can block a cell,s ... a discovery that may explain many of the adverse ... suggest that dietary tryptophan supplements could be a simple ... important drug. Quinine is a very commonly used ...
Cached Biology News:ESHRE launches international study of polar body screening 2What makes a great footballer? 2Tryptophan deficiency may underlie quinine side effects 2
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
in vitro Translation, Accessory Products...
... Origami host strains are K-12 derivatives ... reductase (trxB) and glutathione reductase (gor) genes, ... the cytoplasm. Studies have shown that expression ... than in another host even though overall ...
Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
Biology Products: